Novartis

By Laura Lovett 03:08 pm August 6, 2019
Increasingly, Amazon Alexa and Siri are no longer just a tool for ordering pizza. Voice technology has found its way into healthcare, and now one of the most established industries in the medical world is starting to explore the possibilities of voice: pharma.  “I think voice should be part of a robust ecosystem in which pharma provides treatment information … and things like that,” Kay Bayne,...
By Laura Lovett 01:50 pm July 3, 2019
Diving deeper into digital, this quarter the pharma giants have continued to implement new tools to enhance clinical trials, support medication management with technology and partner in developing digital therapeutics.  Onc, a foreign entity to this established industry, pharma executives are now becoming better versed in working with digital health companies and sharing the lessons they've...
By Dave Muoio 12:03 pm May 21, 2019
Cala Health, a wearable neuromodulation therapy startup focused on chronic diseases, has closed a $50 million Series C financing round. Novartis, Baird Capital, LifeSci Venture Partners, TriVentures and other unnamed backers participated, as did returning investors JJDC, Lux Capital, Lightstone Ventures, Action Potential Venture Capital, dRx Capital and GV. WHAT THEY DO Stanford University...
By Dave Muoio 10:03 am May 21, 2019
This morning Verily announced a series of new strategic partnerships with four global pharmaceutical companies that will bring low-burden digital data collection and analysis tools to clinical research projects. Alongside Novartis, Otsuka, Pfizer and Sanofi, the Alphabet subsidiary will employ its Project Baseline platform to increase the number and diversity of study populations by making it...

Credit: Pilloxa

By Leontina Postelnicu 04:37 am May 9, 2019
Transplant clinics in Sweden will see digital health startup Pilloxa’s innovation be deployed in a new collaboration with Novartis division Sandoz Nordics to improve medication adherence, announced today.   Founded in 2015, Pilloxa has developed a platform that consists of an intelligent pillbox, an app and a cloud solution, along with data driven services, that aims to help patients take their...
Novartis
By Leontina Postelnicu 08:11 am March 4, 2019
Pharma giant Novartis and O2 innovation arm Wayra UK revealed last week that Virtue, TestCard and ExSeed would join its nine-month Health Hub accelerator programme. “After a rigorous judging day, I believe the innovations these three startups offer will make a significant difference to patients and the NHS,” said Novartis Market Access Director Fiona Bride. “I look forward to supporting them over...
By MobiHealthNews 11:25 am December 26, 2018
The pharma industry has become increasingly interested in the digital health space over the last few years, but this quarter numerous projects that have been in the works for years have finally came to fruition. For instance, Pear's reSET, the first digital therapeutic cleared by the FDA, was recently launched to commercial markets.  But that wasn’t the only advance in the space as pharma...
By Laura Lovett 05:37 pm December 10, 2018
The FDA has officially cleared reSET-O — a digital therapeutic to treat opioid use disorder (OUD) jointly developed by Pear Therapeutics and Sandoz, a division of Novartis — a little over a year after it was granted an Expedited Access Pathway designation from the agency.  This announcement makes reSET-O the first digital therapeutic to treat patients with OUD. Patients will need a valid...

Novartis' recently-opened digital health innovation lab in San Francisco. Photo courtesy Novartis on Twitter.

By Jonah Comstock 01:25 pm November 21, 2018
Last month, Novartis announced that it would be cutting 2,200 jobs as part of a restructuring of the company focusing on particular priorities. “The overall strategy we have is to focus the company as a leading medicines company powered by digital technologies,” CEO Vas Narasimhan told STAT News last month. “What that has meant is to exit certain health care sectors or segments … — so we exited...
By Dave Muoio 03:35 pm November 20, 2018
reSET — a substance use disorder treatment that was the first software-only therapeutic cleared by the FDA — is now commercially available for clinicians to prescribe to their patients, according to a release from Pear Therapeutics and Sandoz, a division of Novartis with which Pear partnered back in April. But while physical prescription drugs are usually handled through a pharmacy, the process...